Kendle to Host Conference Call to Discuss Revised 2009 Outlook

CINCINNATI, April 20 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a
leading, global full-service clinical research organization, today announced
that it will not meet analyst expectations for the first quarter of 2009. The
shortfall is due to the impact of unprecedented biopharmaceutical industry
conditions, which are resulting in longer delays in the signing of contracts
on existing awards, fewer new requests for proposals and an increase in
contract cancellations and delays. The Company now expects net service
revenues for the first quarter of 2009 to be well below the market consensus
of approximately $121 million.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080923/CLTU095LOGO )

The Company will host a conference call Tuesday, April 21, at 8:30 a.m.
Eastern Time.

Conference Call and Webcast Details.
Conference Call Details:

Dial in: 866-834-5752 (United States and Canada)
706-643-4051 (Outside North America)

Replay: 706-645-9291
Conference ID Number 95120646

Webcast:

The call will be broadcast live over the Internet and can be accessed at
www.kendle.com or http://www.videonewswire.com/event.asp?id=57853. The
webcast will be archived at www.kendle.com (click on "Investors" shortly after
the call. The conference call and archived webcast will remain available until
5 p.m. Eastern Time on May 21, 2009.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research
organization providing the full range of early- to late-stage clinical
development services for the world's biopharmaceutical industry. Our focus is
on innovative solutions that reduce cycle times for our customers and
accelerate the delivery of life-enhancing drugs to market for the benefit of
patients worldwide. As one of the fastest-growing global providers of Phase
I-IV services, we offer experience spanning more than 100 countries, along
with industry-leading patient access and retention capabilities and broad
therapeutic expertise, to meet our customers' clinical development challenges.

Additional information and investor kits are available upon request from
Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the Company's
Web site at www.kendle.com.

Safe Harbor Statement

Certain statements and information contained in this press release may be
deemed to be forward-looking statements under federal securities laws and the
provisions of the Private Securities Litigation Reform Act of 1995 and Kendle
intends that such forward-looking statements be subject to the safe-harbor
created thereby. All such forward-looking statements, including the statements
contained herein regarding anticipated trends in the Company's business, are
based largely on management's expectations and are subject to and qualified by
risks and uncertainties that could cause actual results to differ materially
from those expressed or implied by such statements. These risks and
uncertainties include, but are not limited to, (a) competitive factors and
industry consolidation, (b) outsourcing trends in the pharmaceutical and
biotechnology industries, (c) the Company's ability to manage growth and
continue to attract and retain qualified personnel (d) the Company's ability
to complete additional acquisitions and to integrate newly acquired
businesses, (e) the Company's ability to penetrate new markets, (f) the fixed
price nature of contracts and cost overruns, (g) the loss, cancellation or
delay of contracts or amendments thereto, (h) the Company's the ability to
maintain existing customer relationships or enter into new ones, (i) the
Company's sales cycle, (j) the Company's ability to obtain financing on terms
acceptable to the Company, (k) the effects of exchange rate fluctuations, (l)
the risks related to the Company's non-US operations and (m) other risks as
detailed from time to time in Kendle's SEC reports, including its Quarterly
Reports on Form 10-Q, Current Reports on Form 8-K and Annual Reports on Form
10-K. In addition, no assurance can be given that the Company will be able to
realize the net service revenues included in backlog and verbal awards. The
Company believes that its aggregate backlog and verbal awards are not
necessarily a meaningful indicator of future results. All information in this
press release is current as of April 20, 2009. The Company undertakes no duty
to update any forward-looking statement to conform the statement to actual
results or changes in the Company's expectations.

SOURCE Kendle International Inc.

Michael Lawson, Investors, +1-513-763-1992, or Lori Dorer, Media,
+1-513-345-1685